Biopharmaceutical Scientist Joins Vitro's Board.

AURORA, Colo. -- Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma announced the appointment of Erik Van Horn, BSCHE to its Board of Directors. Mr. Van Horn is presently employed as a Manufacturing Senior Specialist with Amgen, Inc. Mr. Van Horn is responsible for management of critical manufacturing components in the production of biopharmaceuticals including EPOGEN([R]) and Aranesp([R]). These prescription drugs are used in the treatment of anemia associated with kidney dialysis or chemotherapy, and are both manufactured under strict FDA compliance guidelines to assure safety and efficacy.

Mr. Van Horn obtained his BSCHE degree from the University of Colorado in 1990 with a specialty in biotechnology. He was previously involved with Vitro as its Production Manager in the 1990's and more recently as Vice President of Research. He also has expertise in strategic planning and business development that will be an asset to his position as a director. In addition to serving on the Board, he will also provide consultation to Vitro in biologics manufacturing, quality systems development and bioanalytical methods to assist the Company in the development of new products.

Mr. Van Horn said, "I am pleased to be joining Vitro's Board at this time. I look forward to applying my expertise to assist the Company in the further development of its stem cell products for use in drug discovery and development. Manufacturing of differentiated cell types from precursor stem cells requires novel production technology and I hope that my expertise and experience will assist Vitro in attaining its goals."

About Vitro Diagnostics, Inc.

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCBB: VODG) http://www.vitrodiag.com, has generated over 30 adult stem cell lines from human pancreatic tissues. Vitro owns patent-pending technology for the generation and differentiation of adult stem cell lines and has applied this technology to production of beta islets from stem cell lines generated by the Company. These cell lines may have application in drug development and discovery, diabetes research and therapy. The Company manufactures the VITROCELL[TM] brand of human pancreatic-derived cell lines and related products for research and commercial applications.

Safe Harbor Statement

Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward- looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.